NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Jiangsu Synthgene Biotechnology Co., Ltd.

Jiangsu Synthgene Biotechnology Co., Ltd.

Private
NanjingHealthcare & Life Scienceshttps://www.synthgene-bio.com/

Last Round

Series B

Nov 10, 2021

Total Funding Raised

$174.7M

Company Overview

Jiangsu Synthgene Biotechnology Co., Ltd. is a biotechnology company that provides upstream raw materials and solutions for life sciences, including mRNA, oligonucleotide, and cell and gene therapy manufacturing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Smart Manufacturing, Advanced Materials, Clean Manufacturing

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

synthetic biologybio-manufacturingcontract research organizationCROpharmaceutical intermediatesmicrobial fermentationenzymatic catalysisnucleic acid raw materialsCDMOcontract development and manufacturingcap analogsbiotech supply chaincustom enzyme developmentmRNA raw materialsbiotech lab servicessynbio

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Jiangsu Synthgene Biotechnology Co., Ltd. Comparables

Compare Jiangsu Synthgene Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.

Jiangsu Synthgene Biotechnology Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Yeasen Biotechnology (Shanghai) Co., Ltd.
54%
Hongene Biotechnology
52%
Novoprotein Scientific Inc.
49%

Jiangsu Synthgene Biotechnology Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 10, 2021
Series A ExtensionDec 1, 2020
Series A ExtensionNov 11, 2020
Series ASep 6, 2020
VC RoundJun 20, 2019
Angel
May 22, 2018

Key People

Founding team and executive leadership

Shawn Xiao

Co-founder & Chief Product Officer

Founding Team

Jiangsu Synthgene Biotechnology Co., Ltd. Investors

Notable investors and investment history

Jiangsu Synthgene Biotechnology Co., Ltd. investors
InvestorRounds
Lake Bleu CapitalSeries B
MSA CapitalSeries B
ARCH Venture PartnersSeries B, Series A
Frees FundVC Round, Angel
Chenling CapitalSeries B, Series A Extension
Lilly Asia VenturesSeries B, Series A Extension, Series A
Superstring Capital ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 10, 2021

    $100M round led by Lake Bleu Capital.

  • Sep 6, 2020

    $30M round led by Lilly Asia Ventures.

Jiangsu Synthgene Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Jiangsu Synthgene Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Jiangsu Synthgene Biotechnology Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersNanjing
Employee Range10
Year Founded2018
Last FundingNov 10, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.